All bar one of the suspended drugs contain the NSAID flunixin. The other affected drug is the antibiotic, Tribrissen:
Allevinix 50 mg/ml Solution for Injection for Cattle, Pigs and Horses (Ceva Animal Health)
Cronyxin Injection, 5% w/v Solution for Injection, for cattle and horses (Cross Vetpharm Group Ltd)
Finadyne 50 mg/ml Solution for Injection for cattle, pigs and horses (Intervet UK Ltd)
Flunixin 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (Norbrook Laboratories Limited)
Meflosyl 5% Solution for Injection for horses and cattle (Zoetis UK Limited)
Norixin 5% Solution for Injection for cattle and horses (Norbrook Laboratories Limited)
Pyroflam 50 mg/ml Solution for Injection for Cattle, Horses and Pigs (Norbrook Laboratories Limited)
Tribrissen 48% Suspension for Injection for horses, pigs and cattle (Intervet UK Ltd)
The British Equine Veterinary Association says that the decision to suspend the drugs was taken without consultation with the veterinary profession, and is urging the VMD to overturn the suspension in horses not destined for the human food chain, to reduce the potential impact on equine welfare.
Jonathan Pycock, BEVA president said: "BEVA is fully supportive of all attempts to promote food safety, however flunixin is widely viewed as the gold-standard pain killer in horses and is commonly used in horses undergoing both elective and emergency surgery, for the crippling pain associated with laminitis and for severe forms of colic.
"BEVA is calling on the VMD to immediately enable limited batch release of flunixin for use in horses not destined for the human food chain in the interests of animal welfare. The equine veterinary profession has always been open to consultation with the VMD on a range of important matters relating to responsible medicine use, antibiotic resistance, horse identification, passports and the horse meat issue. BEVA is perplexed as to why the VMD failed to consult with the equine veterinary industry on the animal welfare impact of withdrawing such an important drug.”
The ten-minute online survey aims to gather a snapshot of horse health over the period of a week.
The results help to identify trends in endemic equine diseases and help the Blue Cross steer equine awareness, education and research.
This year the survey includes some welfare questions to help guide knowledge in response to what the charity calls 'the UK’s horse welfare crisis'.
The National Equine Health Survey is run by the Blue Cross in partnership with the British Equine Veterinary Association. Dodson and Horrell is helping to cover the costs of running the scheme.
Supporters of the survey include the British Horse Society, Horse Trust, Redwings and the Pony Club.
Medal-winning riders Mary and Emily King, and Yazmin Pinchen (pictured right) also support the survey.
Visit www.bluecross.org.uk/NEHS or email NEHS@bluecross.org.uk to register and take part, which carries the chance of winning prizes including Star Lister Clippers, a Lister Adagio Trimmer and some Burford Ariat boots.
Participation in this year’s survey was similar to previous years with 5,235 people taking part and returning records for 15,433 horses. Most horses were kept in livery or a private yard and used for leisure and hacking and the majority within the age range of 5 to 10 years.
A broad variety of breeds were represented, including natives, thoroughbred types and warmbloods.
59% of horses were recorded as healthy and 41% with one or more health problems, compared to 62% and 38% respectively in 2016.
The top five disease syndromes recorded this year were:
Of the 5.5% of horses recorded with back problems 26% were also showing signs of lameness. While the details of the results do not confirm that the two are necessarily connected, these findings reflect the outcome of recent studies conducted by Dr Sue Dyson, Head of Clinical Orthopaedics at the Centre for Equine Studies at the Animal Health Trust.
Sue said: "It is a common observation that horses with lameness stiffen the back as a protective mechanism and develop muscle pain which may be misinterpreted as a primary back problem. We have shown objectively that abolition of lameness by diagnostic analgesia results in an immediate increase in range of motion of the back. The current data supports this close relationship between lameness and back pain."
HRH The Princess Royal has opened the Animal Health Trust's new cancer treatment and research facility in Suffolk.
The facility has been purpose-built to treat horses, dogs and cats with cancer. It will also assist in furthering understanding of the disease in animals.
Peter Webbon, Chief Executive of the AHT, said: "2012 marks 70 years of the AHT fighting disease and injury in animals, and the addition of the Cancer Centre is a landmark achievement in our history. We believe this is the first facility of its kind in Europe, purpose-built to treat horses, dogs and cats with cancer. We now have a short commissioning process to undertake but anticipate welcoming the first patients through the doors in early 2013."
The Kennel Club Cancer Centre at the AHT houses a linear accelerator (pictured right) and brachytherapy machine used in radiotherapy treatment, along with a 16-slice CT scanner to aid radiotherapy planning.
The new facility complements the AHT's existing cancer treatment options of surgery and chemotherapy meaning the Suffolk-based charity will be able to offer each and every patient the very best options for their specific case, whatever the diagnosis. With one in four dogs and one in six cats developing cancer at some time in their life the new centre will help many more animals fight cancer.
Peter Webbon, added: "It was thanks to a generous donation from the late Tom Scott, a long-term supporter of the AHT, that we were able to start this development. His donation, along with that from many other AHT supporters, and an interest-free loan of £1.5 million from the Kennel Club has meant this ambitious project has come to fruition so quickly."
It has taken just over a year to build the Cancer Centre which contains more than 2,600 tonnes of concrete and has eight-feet wide solid concrete walls.
On opening the facility, HRH The Princess Royal, President of the AHT, said: "This Cancer Centre is an exciting development at the AHT and will make a real difference for animals with cancer, here and now. It will improve the chances, for many animals, of beating this pernicious disease.
"Countless other horses, dogs and cats across the world with cancer, who will never be seen by an AHT clinician, will also benefit from knowledge gained from research in The Kennel Club Cancer Centre at the AHT."
The AHT has a strong history in cancer research and the Kennel Club Cancer Centre will enhance the charity's well established cancer research programme. Knowledge gained through the treatment of animals in the facility will contribute to the study of cancers, their causes, early diagnosis and treatment, and ultimately hopefully the prevention of some forms of the disease.
Steve Dean, Kennel Club Chairman, said: "I am very proud to be here today to celebrate the opening of the Kennel Club Cancer Centre. Thanks to the expertise available here at the Animal Health Trust, the Cancer Centre will provide advanced techniques for the diagnosis and treatment of cancer, to the benefit of many animals. It is exciting to consider how synergy between the Kennel Club Cancer Centre and the Kennel Club Genetics Centre can help to further the understanding of the inheritance factors that influence the development of cancer."
A new study1 published in the Equine Veterinary Journal's (EVJ) special American Association of Equine Practitioners supplement has concluded that maggots can play an integral role in modern veterinary care for a variety of wounds in horses.
The study assessed the efficacy of maggot debridement therapy in a diversity of equine lesions and found that the method was beneficial in 93% of cases.
Maggots have been used for the treatment of wounds for hundreds of years. Freshly emerged, germ-free larvae of the common green bottle fly are usually used for the purpose. Their wound-healing action is attributed to a debridement effect, an antiseptic effect, a direct effect on cytokine and cell proliferation involved in wound healing and breakdown of biofilm formation. Maggots also destroy and digest bacteria and may also be beneficial in the fight against multi-drug-resistant bacteria such as MRSA.
The study involved the retrospective analysis of 41 horses with various lesions including foot injury, limb laceration, soft tissue abscesses and musculoskeletal infection. Depending on the type, size and location of the wound the maggots were applied either in direct or indirect contact. In some cases a second maggot application was necessary to reach the desired level of healing. Debridement, disinfection and healing occurred in all but three cases, in less than a week. Of the three that did not respond two were complicated by the presence of tumours and one by pre-existing damage to the underlying bone.
Olivier Lepage of the University of Lyon, who led the study, said: "These results show that maggot debridement therapy potentially has an integral place in modern veterinary wound care. It can be used to treat many types of lesions, although not those involving tumours or bone sequestration. Associated high costs present a limiting factor but maggot debridement therapy should certainly be considered for lesions that fail to respond to conventional methods."
Professor Celia Marr, Editor of the EVJ, said: "Horses often suffer from non-healing wounds, particularly in the limbs where the skin is under continuous movement and there is very little subcutaneous tissue. Although at first glance this study might seem counter-intuitive and we might think of maggots as being the last thing one would want on a clean wound, it shows that maggots can be an effective way to clear damaged tissue and this is an important adjunctive approach in equine wound management."
1The use of maggot debridement therapy in 41 equids OM Lepage, A Doumbia, MF Perron-Lepage and M Gangl. EVJ ISSN 0425-1644 DOI: 10.1111/j.2042-3306.2012.00609.x
The study is published by Wiley-Blackwell and can be accessed at http://onlinelibrary.wiley.com/doi/10.1111/j.2042-3306.2012.00609.x/abstract
The manufacturer has identified that there is a potential for decreased levels of the preservative Chlorobutanol hemihydrate in the following batch: J2101-03 Expiry 11/2018.
Oxytobel is distributed in the UK by Bimeda UK. Veterinary practices that have purchased this batch number should contact Bimeda to arrange collection.
Any queries in relation to return of the product or credit for the product returned should be addressed to Kay Cowton, Bimeda UK Sales on 01248 725400 or email: uksales@bimeda.com
For further information on the recall please contact Bela-pharm GmbH & Co.KG: +49 (0) 44 41 873 294.
Merial has announced the UK launch of updated ProteqFlu, the first and only EI vaccine in Europe to contain a clade 2 strain.
The company says the new vaccine is also the only one that is fully compliant with the latest 2014 OIE recommended EIV strains.
Louise Radford MRCVS from Merial said: "The launch marks the UK's first and only fully updated equine flu vaccine that contains both a Clade 1 and Clade 2 antigen which includes protection against the latest Florida Clade 2 strain, Richmond 07. This is a significant step for horse health, and the equine industry as a whole."
Hervé Poulet, Merial's head of BioDevelopment and BioResearch said: "Merial has developed strong and unique expertise in the development of non-replicative recombinant canarypox virus-vectored vaccines for various species and diseases.
"For the development of ProteqFlu, our non-replicative recombinant canarypox vector expressing the EI virus haemagglutinin (HA) is used because of its ability to induce a strong cellular immunity which is an essential component in protecting against this highly contagious disease."
Louise added: "ProteqFlu has also demonstrated its success and efficacy in real outbreaks, particularly during the last major outbreak, in Australia in 2007. ProteqFlu was the only vaccine chosen for the eradication programme."
Elanco, a division of Eli Lilly and Company, has launched into the UK companion animal market with a pledge to listen to vets and provide a highly personalised level of support.
The company will initially offer recognised brands such as equine vaccines from the Duvaxyn range, Felocell vaccine for cats and equine wormer Strongid P. It says it is also developing a range of innovative new products designed to address the unmet needs of companion animals, the first of which are expected to be launched during 2011.
Mrs Tina Hunt, a Glasgow Vet School graduate and most recently, Veterinary Business Director at Fort Dodge UK, has been appointed with a remit to build the Elanco Companion Animal Health organisation in the UK. Reporting to Jannes Nijland, Director Elanco Western Europe, she will spearhead the company's growth and relationship building with veterinary practices across the country.
Tina said: "Recent changes in the animal health sector make it an exciting time to be launching a new companion animal brand. The opportunity to be in at the start and to shape a completely new business from scratch was too good to miss. My team shares a passion to combine the best of our experience with new approaches and new ways of working which are more closely attuned to what vets actually want. This means doing things differently and this is a challenge we relish.
We seek a genuine partnership with the profession and look forward to building close, individual relationships with vets and practices, helping them to enable companion animals to live longer, healthier and higher quality lives. While we're a newcomer in this sector, we benefit from the track record and resources available to Elanco, the fifth largest animal company in the world. We're determined to make Elanco Companion Animal Health a trusted and valued partner to vets working in companion animal practice."
Elanco develops and markets products to improve animal health and food-animal production in more than 75 countries. The company employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a pharmaceutical corporation. Additional information about Elanco is available at www.elancopet.com and the company can be contacted via email: elancoCAH.uk@lilly.com
Animal Health and Veterinary Laboratories Agency (AHVLA) has announced the formation of a new independent advisory group to recommend a future delivery model for veterinary surveillance in England and Wales.
The Advisory Group will be chaired by Dirk Pfeiffer, Professor of Veterinary Epidemiology at the Royal Veterinary College. According to the AHVLA, it will include representatives from government, the veterinary profession and the livestock farming and private laboratory industries and is being created so all those with an interest in veterinary surveillance can shape a future model and ensure that all issues are thoroughly considered.
Veterinary surveillance seeks to identify new or re-emerging threats to our livestock population and to public health. It involves a partnership approach between livestock keepers, private veterinary surgeons, the Scottish Agricultural College, industry bodies and AHVLA in order to effectively gather and assess intelligence.
AHVLA is seeking to identify ways to undertake veterinary surveillance both more effectively and at an affordable cost to the taxpayer. Work in this area has been on-going since 2010, and the merger of the former Animal Health and Veterinary Laboratories Agency (VLA) has created opportunities to review how veterinary surveillance can best be delivered.
The new model will aim to address capacity imbalances in the current service where provision sometimes outstrips demand. The independent advisory group are also expected to recommend how better and closer working methods across the partners can make the surveillance stronger as well as more cost effective.
Surveillance has historically been based on in-depth investigation of disease incidents with an emphasis on post mortem examinations carried out at AHVLA's regional laboratories. This system is a key element in the government's risk-based approach to the management of animal disease related threats.
AHVLA says that the current model, although successful in identifying diseases in the past, can be improved upon. A recent internal AHVLA report identified viable options for achieving better surveillance at the same or lower cost by, for example, exploring moving towards risk and intelligence based surveillance and improving the value added by working more closely in partnership with vets and their farmer clients and other sources of intelligence data.
In mid-January 2012, AHVLA will also be publishing, and publicising, an online survey aimed at individual veterinary practioners and livestock keepers. The survey will seek individual opinions on the inputs, mechanisms, outputs and value of surveillance in England and Wales Work is expected to run until spring 2012, following which recommendations on a way forward will be made.
Carl Padgett, President of the BVA, said: “Veterinary surveillance is an essential component in our animal health, public health, food security, and international trade work.
“The emergence of Schmallenberg virus in ruminants in northern Europe demonstrates the current value and ongoing need for a robust surveillance system to work both nationally and internationally.
“The BVA welcomes the establishment of the advisory group and particularly the wide range of veterinary expertise and experience that is represented on the group. It is important that views from both veterinary practitioners and veterinary scientists are fed into this review.
“While we understand that AHVLA and Defra must ensure value for money from the surveillance network, any future model must be shaped by good surveillance strategies, not the need to cut costs.
“We urge all practitioners in England and Wales to contribute to the discussions by completing the online survey.
“We look forward to engaging with the advisory group as it carries out the review and beyond.”
The survey of 50 vets carried out in May this year1 found that only half of them are recommending strangles vaccination to their clients.
They also felt that horse owners could be doing more to combat the disease.
Less than half of vets questioned believed that yards and premises operated good biosecurity measures prior to a strangles outbreak, yet 85% brought in more stringent biosecurity after an outbreak, when it was too late.
Dechra says that vets and horse owners can help combat the estimated 300 outbreaks of strangles each year with the following steps:
Sara Barker BVSc CertAVP(EM) MRCVS, equine field support manager at Dechra, said: “Strangles is one of the most common equine infectious diseases both in the UK and worldwide and a multi-factor approach is key to tackling the disease.
"Strangles vaccination is recommended, alongside good biosecurity, quarantine measures and regular temperature checking.
"By working together, vets and horse owners can help to keep horses healthy and prevent the spread of strangles.”
Reference
The Waltham Equine Studies Group has announced the results of two pieces of research designed to improve understanding of the best nutritional support for older horses, whether they are healthy or diagnosed with Pituitary Pars Intermedia Dysfunction (PPID or Cushing's).
The first study: A comparison of nutrient digestibility between adult and aged horses, conducted by the Department of Large Animal clinical Sciences and Animal Science, Michigan State University and The Waltham Equine Studies Group, confirmed (in contrast to earlier work) that there was no difference in digestibility between healthy adult and aged horses when fed a variety of common equine diets.1
In the second study: Characterisation of the faecal bacterial community in adult and elderly horses fed a high fibre high oil or high starch diet, the Institute of Biological Environmental and Rural Sciences, Aberystwyth University, The Waltham Equine Studies Group and Michigan State University used the same horses as the previous study but this time looked at their gut microflora. The results showed that although no significant differences in individual species of bacteria were found, ageing was, however, associated with a reduction in bacterial diversity. This, say the authors, may in part explain why older animals can be at increased risk of intestinal disturbances.2
An abstract that summarised part of the Waltham Equine Studies Group's work on the effect of additional supplementation on aged horses with and without PPID was presented at the 2nd Dorothy Havermeyer Geriatric Workshop in the USA last November.3 This work, carried out in conjunction with Dr Amanda Adams at the University of Kentucky showed that age is key in influencing inflammation and metabolism rather than whether the horse is PPID positive or not.
Professor Pat Harris, head of the Waltham Equine Studies Group, said: "For the parameters we monitored, the research showed that it is being old that is the issue, rather than having PPID."
Clare Barfoot RNutr and the research and development manager at Spillers said: “This should give us a better understanding of the effects of diet and age on metabolism in order to determine optimal nutrition for the senior horse. Preliminary work suggests that this new research may change the way we think of feeding the older horse. Waltham’s work continues to ensure that Spillers feeds remain at the forefront of equine nutrition, for the better health of horses everywhere.”
References
Rominervin contains 10 mg/ml romifidine hydrochloride, equivalent to 8.76 mg romifidine, presented in a 20 ml vial.
It can be used as a sedative to facilitate handling, examination, minor surgical interventions and minor procedures or as a premedication prior to administration of injectable or inhalation anaesthetics.
Rominervin can also be used in combination with synthetic opiates such as butorphanol to provide deeper sedation or analgesia.
Dechra Brand Manager Emma Jennings said: "Rominervin is highly effective as it has a longer duration of action than other alpha-2 agonists1. It starts to work within one to two minutes with maximum sedation achieved between five and 10 minutes.
"It is yet another valuable addition in our equine anaesthesia and analgesia range that has been designed to provide vets with the therapies they need to operate successfully in day-to-day practice."
Rominervin can be used in conjunction with Dechra’s equine anaesthesia and analgesia app, designed to help veterinary professionals choose optimal anaesthetic protocols and calculate anaesthetic drug doses and administration rates.
For more information visit: www.dechra.co.uk/products/equine
The aim of the week is to focus equine practices on ‘Taking care of the small things that make a big difference’ with a toolkit of resources designed to help them promote their businesses and educate and promote the benefits of preventative healthcare.
Peter Young, MSD Equine Business Manager said: "This year’s Horse Health Week has been created to focus on the small things we can all do to help keep our nation’s horses happy and healthy. We are encouraging equine vets to get involved and engage with their clients throughout the week with the support of our toolkit. This celebration of Britain’s horses and the things we can do to improve their health is a positive opportunity for vets to build client loyalty and attract new clients. I urge practices to do as little or as much as they can, but I urge them to do something!"
Horse Health Week is supported with a range of materials for both practices and clients, along with social media content, which vets can obtain on a USB stick from their MSD Animal Health Equine representative.
The toolkit includes a series of five animations – one for each day of the week. They each cover a different topic including; horse connections, the importance of hand washing, equipment at shows, isolation and vaccination. There is also a social media campaign for practices to run called #BonVoyageBuzz, and a survey that will gather the views of horse owners on preventative healthcare.
For full details talk to your MSD Animal Health Account Manager, call MSD on 01908 685685 or refer to www.healthyhorses.co.uk/horse-week.
Until the arrival of Computed Tomography (CT) and Magnetic Resonance Imaging (MRI), radiographs were the only feasible option. More recently, the availability of bigger, wider and more adaptable scanners has allowed horses to be examined in a standing position, significantly improving diagnostic and treatment strategies and avoiding the need for general anaesthetic.
Against this background the collection considers the advantages of cutting-edge modalities and draws comparisons with more readily available tools such as radiography.
Given the increase in use of CT in horses and the contamination hazards faced particularly by horse handlers, two practical articles in the collection describe the role of equine head CT, how to set up standing equine CT and the radiation exposure risks.1,2
The most revolutionary recent advance in diagnostic imaging for dental disease in horses is CT. However, a study of horses with diseased mandibular cheek teeth found that while CT is useful to identify defects in the bone and tooth it is far less useful for the identification of inflammation and tissue destruction which is far better served by MRI.3
The structure of the equine head is complex and subject to great variation so several articles focus on practical anatomy and interpretation of radiographs of this region.4.5 Advanced diagnostic techniques are helping with clinical and surgical approaches to problems with the equine head. The sphenopalatine sinus is challenging to assess radiographically because of its tricky position but CT can help overcome this obstacle. One of the studies describes how CT can help unravel the pathology of various equine sinonasal tumours. Other articles cover less common pathological conditions including the historical, clinical, diagnostic imaging findings and outcomes of five horses with pneumocephalus. 6,7,8
Practitioners recognise MRI as the gold standard for neurologic imaging because of the excellent soft tissue detail but the size of horses and the size of scanners makes it a challenge to use. An additional constraint is the longer acquisition time compared to CT. Notwithstanding these limitations three studies in the collection display the various benefits of using MRI for the spine and neck, including the evaluation of 84 equine head disorders, the diagnosis of cervical stenotic myelopathy, and the assessment of two foals with closed head trauma.9,10,11,12
Despite the significant advances in imaging, the horse’s back is still defying conventional systems, primarily because of its size, concludes a spinal evaluation article. New technologies such as robotic fluoroscopy and cone-beam CT, may provide a cross-sectional method to evaluate the equine spine, but for now radiographs are still better to help evaluate findings of spinous process impingement seen on scintigraphy. The take home message here is that the wide variety of abnormalities seen on scintigraphy and radiography in horses with and without back pain makes a diagnosis more likely to be achieved by physical examination rather than the imaging findings.13
Anthony Pease, associate editor of the EVJ said: "Advanced imaging is still in its infancy with sequences still being developed to help optimise the time and detail needed for diagnosing complex musculoskeletal and neurologic disorders. Continued research in a controlled environment and comparing to histopathology will allow clinicians to further their knowledge and understanding of the CT and MRI findings in the equine patients."
Intervet/Schering-Plough Animal Health has announced that it is to sponsor the Equine Business Management Strategies (EBMS) program, a targeted business education program developed for equine veterinary surgeons and practice professionals.
According the company, this 5-day course has proven very successful in the United States. It had its European kick-off in Amsterdam on August 22, 2010, where a group of almost forty equine practitioners from North America and Europe gathered to discuss and learn how to apply business principles in their day-to-day work. The program was chaired by Dr. Joop Loomans, an equine veterinary surgeon responsible for equine business management education at the Department of Equine Sciences of the Veterinary Faculty of Utrecht University (The Netherlands).
Course participants worked with international specialists on strategic planning, benchmarking, branding and change management to create strategic plans to implement at their practices, and to share their knowledge, experience and ideas.
Intervet/Schering Plough says the launch of Equine Business Management Strategies program exceeded expectations of participants, sponsor and organizers. The chance to look at the day-to-day practice from a different angle and to learn about things like benchmarking exercises, revenue analysis and branding was highly appreciated. Participant Jeremy Mantell from Liphook Equine Hospital in the UK said: "The EBMS has given me a clearer understanding of what I need to change and develop in my practice."
Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering-Plough Animal Health said: "We believe that running an equine practice is not based solely on technical and scientific skills but also on effective practice management. That is why our company has decided to support this initiative. Intervet/Schering-Plough Animal Health also continues its custom of providing not only innovating products, but also new, value-added services to strengthen its bond with veterinarians."
A team of researchers led by Tim Mair, CVS Equine Veterinary Director and Specialist in both Equine Internal Medicine and Equine Soft Tissue Surgery at Bell Equine Veterinary Clinic, will review 100 cases of colitis in adult horses and 100 controls referred to seven equine veterinary hospitals in the UK: five CVS equine veterinary hospitals as well as Rossdales Equine Hospital and University of Liverpool’s equine hospital.
A set of diagnostic tests on blood and faeces will be performed in these cases.
The laboratory tests will include: small redworm serology, culture and PCR of faeces for Salmonella spp, PCR of faeces for Clostridioides difficile and Clostridium perfringens, ELISA of faeces for toxins of C.difficile and C.perfringens, PCR of faeces for coronavirus.
The clinical features, laboratory results, treatments and outcomes will also be recorded.
Tim said: “Acute colitis accounts for around 5% of admissions to referral hospitals.
"And of those who are referred with it, half will not survive but there is very limited evidence available.
"So it’s vital that we build our evidence-base of this life-threatening condition.
"We hope that the outcomes of our new study will lead to a greater understanding of the causes and better inform veterinary treatment of colitis in UK adult horses.”
The Colitis in Adult Horses study is supported by a research grant from CVS, and funding for the small redworm ELISA will be given from Austin Davis Biologics.
The study started at the beginning of 2024 and the first horses have been recruited.
The results of the study are expected to be published in 2025.
Apparently, there were over 100 times more recorded outbreaks of equine flu across the UK in 2019 than the year before1, and numerous equestrian events were cancelled as a result.
The company says that despite this, as of 2019, only about half of all UK horses are vaccinated2.
Blaise Scott-Morris MRCVS, Equine Marketing and Technical Manager at MSD Animal Health said: "Last year’s outbreaks of equine flu rocked the equine world, raising important animal welfare issues and costing the racing industry millions.
"Furthermore, they highlighted the need for good preventative healthcare and, in particular, vaccination. It’s vital that more owners are encouraged to vaccinate and those that already have, to keep up with their annual vaccinations and health checks so we don’t experience the same suffering again."
MSD's campaign invites horse owners to join the movement to #fightequineflu, and there is a range of materials to help practices promote the campaign and encourage clients to talk about vaccination and preventative healthcare, including an educational infographic poster, a social media pack and new resources on the Chameleon appointment reminder system.
MSD will itself be promoting the campaign on social media (Facebook: @Keeping Britains Horses Healthy, Instagram: @KeepingHorsesHealthy), and through partnerships with consumer channels such as Horse and Country TV.
There is also a new information resource online at www.kbhh.co.uk/achoo, which offers horse owners links to a range of other educational preventative health materials and horse care advice.
To request your Fight Equine Flu practice pack, speak to your MSD account manager.
VetSurgeon member Viki Edmondson MRCVS is taking part in a drive to help 13-year-old Octavia Woodward, who was born with spinal muscular atrophy (SMA), raise £100,000 to help The SMA Trust.
Viki, a well-known vet in the carriage driving world, will be joining Octavia on 'Octavia's Mad Marathon', a five-day, 110 mile carriage drive from Windsor to Wincanton.
Octavia will be driving her pony, Diddy, with her mother Henrietta as co-driver. Meanwhile, Viki will be driving a pair of Gelderlander horses. They'll be leaving the main ring at the Royal Windsor Horse Show with a support crew at 3:30pm on 13th May.
Viki graduated from Bristol Veterinary School in 1993. Since 2001 she has run her own equine practice plus a small animal surgery from the Newdigate, Surrey farm she shares with husband Peter. Viki has known Octavia since she was born and it was Viki who paired up Diddy with Octavia and encouraged her to progress from walking round the roads to the excitement of "off-roading". Viki will be providing support and encouragement to Octavia during the trip - of course with any veterinary help being close by.
To support Viki and Octavia, visit: http://www.justgiving.com/vikithevet
BCF Technology has launched a competition to win a top of the range digital radiography system from its Cuattro range for 6 months.
To enter the competition, you need to record a short video (up to 2 minutes) explaining how the DR system would transform your imaging function. BCF is asking entrants to be as creative as possible as the voting will be open to the public. The company will pick a shortlist of finalists and then invite the public to vote for a winner on its Facebook page and website.
The competition is open to both small animal and equine vets, for the following systems:
Sarah O'Grady from BCF said: "Having a Cuattro DR system could make a huge difference to either a small animal or an equine practice. For a small animal vet practice that doesn't currently have a DR system, they will love the difference it makes to X-ray studies. Diagnostic images are produced in seconds and re-takes are almost non-existent. A Wireless Slate 3+ can greatly improve the ease of in-stable operations and procedures. With the removal of wires, these procedures run much smoother. You will also be surprised by the improvement in image quality."
The closing date for the competition is 30th November 2013.
To enter your video:
The winner will be required to arrange insurance for the system during the time they have the system. Full terms and conditions can be found on the BCF website.
To find out more visit the BCF website or Facebook page or call +44 (0)1506 460 023.
The BEVA has welcomed the news, whilst expressing its concern that the drug was suspended without consultation with the veterinary profession in the first place.
Jon Pycock, BEVA President said: "It remains a concern to BEVA that this mechanism was not put in place before the suspension of flunixin was imposed. Contrary to assertions by the VMD, wholesalers were unable to meet the demands of the veterinary profession and clinical use of this medicine was disrupted within 24 hours of the VMD’s initial announcement.
"We are surprised by the Regulator’s lack of awareness of availability in the supply chain and question why there was no consultation with the veterinary sector before the suspension was enacted. The VMD has been aware of this issue since March 2018 and it appears that no contingency was put in place to consider the animal welfare impact of this decision until it was too late."
BEVA Junior Vice President and Specialist in Equine Surgery Tim Mair continued: "Flunixin is a unique medicine in managing pain and sepsis in horses with colic. The VMD appeared to believe that this medicine could be substituted for other veterinary medicines and this is simply not the case. The release of stock from manufacturers is a short-term solution and, looking forward, we would like assurances that the VMD will fast track applications for the modification of product licenses to ensure that equine vets have continued access to these products."
Professor Kate White, Senior Vice President of the Association of Veterinary Anaesthetists added: "Provision of pain relief is essential to maintain animal welfare. The loss of these products would hinder the work of vets working with horses and donkeys and in zoos where they are first line drugs for the management of pain. Use of flunixin in these animals can be undertaken safely with no impact on human health."
Stock of flunixin held by manufacturers will be distributed alongside a ‘caution in use’ letter that will explain the restricted use of this product. BEVA is reminding all equine vets that the horse’s food chain status must be checked when using this product – either using the paper passport or the recently launched chip checker on the central equine database website.
MSD Animal Health's equine division has launched a new series of materials to support its Keeping Britain's Horses Healthy Campaign.
For veterinary practices, there's a Vet Reception Pack designed to help receptionists educate owners why they should vaccinate and the benefits of preventive healthcare.
For yards, there are posters giving guidance and advice on prevention of Infectious Respiratory Disease and the steps which should be taken to control a potential outbreak. They can be tailor made for an individual yard.
Peter Young, MSD Animal Health Equine Business Manager said: "Our first wave of support materials focused very much on equine vets and owners - helping raise awareness of the importance of preventive healthcare and driving owners towards vets for advice. This phase of materials helps support yard owners and receptionists, aiming to fill some of those communications gaps where advice and guidelines on individual horse's vaccination requirements and yard protocols can play a vital role in preventing the spread of disease and controlling outbreaks."
Keeping Britain's Horses Healthy is a national campaign to educate horse owners on endemic infectious disease, vaccination, herd immunity and the importance of preventative healthcare. It includes a range of educational materials for veterinary surgeries and direct to owners. The campaign is supported by a national PR, advertising and social media programme, together with a dedicated website www.healthyhorses.co.uk. The website, aimed at driving owners back to their veterinary practices, includes a vet finder, exclusively for equine practices, and healthcare information.
For full details of the launch programme, talk to your account manager, call 01908 685685 or visit www.healthyhorses.co.uk.
Dechra Veterinary Products has launched a new online fluid therapy distance-learning course for vets and nurses, to help maximise the potential of its Vetivex® fluids range.
The Fluids Knowledge Programme has been created to provide comprehensive and flexible online CPD for companion animal and equine practitioners. The coursework, which counts for six to eight hours of CPD learning, includes the latest thinking from fluid therapy specialists Dr Ava Firth, Karen Humm and Kevin Corley.
Dechra says the course combines theoretical and practical advice on fluid therapy for both small animals and horses, and can be used for training, as a refresher, and to develop thinking on fluid therapy. Self-assessment questions included within the course allow progress to be monitored throughout.
Gwenda Bason, marketing director for Dechra Veterinary Products, said: "We've spent months of research and development producing this online learning portal for professionals. It will enable vets and nurses to improve their knowledge, understanding and patient care. Being online, users can dip in and out of it as and when their schedules allow and additional costs often associated with CPD learning, such as travel or accommodation costs, are eliminated.
"When practices choose Vetivex, they're not just buying bags of fluid, they're benefitting from our investment in practice education which will improve their understanding of the role and management of fluids."
Dechra estimates the programme is worth around £400 per person, and therefore offers savings of over £3000 in CPD costs for an 8 member practice.
To find out more about the Fluids Knowledge Programme visit www.fluidtherapy.co.uk, or contact Liz Rawlings at Dechra on 01743 441 632.
Hand-mouldable into any shape, Hoof Repair is used to create prosthetic hoof extensions and additions that restore foot integrity.
The company says there is no exothermic reaction when the thermoplastic hardens, which eliminates issues caused by excessive heat and makes the product suitable for treating acute laminitis, cracked hooves and horses that have lost a lot of hoof.
When used with Imprint Structural Adhesive, Hoof Repair forms a bond with hoof wall which can be nailed into and rasped, and will stay in place as hoof grows. Hoof Repair is also suitable for treating foal foot deformities.
The company says Hoof Repair is often used in conjunction with Imprint shoes, which are made of the same low melt, long lasting thermoplastic. It allows extensions to be made to the shoes and together the Imprint system protects and supports the hoof allowing the foot to flex and move freely.
Andrew Poynton, Imprint’s Inventor said: "Hoof Repair forms part of a foot care system that has been developed over 20 years by farriers in association with veterinary surgeons. Hoof Repair assimilates hooves precisely to retain the foot integrity and it is particularly useful for treating acute laminitis and cracked or badly damaged hooves."
Henry Schein said in a statement on Friday that it had sold the business in order to focus on its dental and medical markets and pursue new investment opportunities.
Covetrus says it will be using the experience, technology and global scale of the merged companies to provide veterinary practices with a more comprehensive set of integrated services and technology solutions, and tools to strengthen client relationships and grow their practice.
Covetrus launched on Nasdaq last Friday, when President and Chief Executive Officer Benjamin Shaw, said: "Today marks an important new chapter in the world of veterinary medicine, as we launch Covetrus as a new company listed on Nasdaq.
"We look forward to strengthening our customer relationships and expanding our veterinary practice partnerships worldwide as we bring more comprehensive and powerful solutions to market to meet their evolving needs and improve health and financial outcomes."
A free copy of the compendium has been sent to every veterinary practice in the UK, and it is also available online at: www.noahcompendium.co.uk. A special edition of the book commissioned by AMTRA will also be available for its SQPs shortly.
NOAH chief executive Dawn Howard said: "The NOAH Compendium, in all its formats, remains a major part of NOAH’s efforts to ensure appropriate access and responsible use of medicines for all animals. We are pleased it is even more comprehensive this year, as we continue to expand its list of contributors.
"Every NOAH member, as well as the non-member participants in the NOAH Compendium, is a signatory to the NOAH Code of Practice on Promotion, which demonstrates their commitment to operate above and beyond any regulatory requirements."
She added: “As well as product datasheets, the Compendium includes another vital resource – the contact details for each participating company. Company veterinary and technical advisors have detailed knowledge about their company’s medicines. The NOAH Code includes the requirement for NCAH qualification for NOAH staff in technical dialogue with prescribers and users of animal medicines – meaning their advice can be regarded as a valuable and trusted resource. They are ready to talk to prescribers about the use of a medicine in a particular animal or in a particular situation, as well as to explain any queries about the data sheet."
Veterinary practices that have not yet received a copy, perhaps because they are new or have changed address in the past year should contact NOAH (noah@noah.co.uk).
Extra copies are also available to order, for £47.50. Special prices are also available for bulk orders.